Combination treatment for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination treatment for extensive-stage small cell lung cancer. You would receive an immunotherapy drug (adebrelimab) together with chemotherapy and a very low dose of chest radiation, to see if this helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are able to take care of yourself and do light daily activities (ECOG score 0 or 1).
- Your doctor has confirmed that your small cell lung cancer is extensive-stage (has spread beyond one lung).
- You have not had any chemotherapy or radiation for extensive-stage small cell lung cancer before this study.
- You have not had radiation to your chest in the past, and you are not planning to have it during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of immunotherapy (adebrelimab) with chemotherapy and radiation as the first treatment for extensive-stage small-cell lung cancer. It aims to see if this approach can help control the cancer better than standard treatments.
This trial tests a combination of three drugs—an immunotherapy (adebrelimab), a targeted therapy (famitinib), and chemotherapy—for people with extensive-stage small cell lung cancer. The goal is to see if this triple combination works better than standard treatment.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy and radiation for limited-stage small cell lung cancer. After the initial treatment, the drug is continued to help keep the cancer from coming back.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.